Clinilabs, a leading specialty contract research organisation (CRO) focused on central nervous system (CNS) drug and device development, has announced leadership expansion. Laura Shannon joins the organisation as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson. This expansion of the senior leadership team is a recognition of a growing organisation with global capabilities and continuing commitment to advancing treatments for patients with psychiatric and neurological disorders.
Ms. Shannon is a dynamic leader with more than 30 years of biopharma industry experience, known for her ability to build high-performing teams, forge strategic alliances, and drive growth across complex organizations. Most recently serving as EVP and Chief Commercial Officer of the US and Canada regional business units at IQVIA, where she led a nationwide multibillion-dollar sales and account management team across R&D, Real World Solutions, and Commercial Solutions. Throughout her career, Laura has held broad global leadership roles across large and midsize pharma, emerging biopharma, and medtech companies.
This expansion of the senior leadership team is a recognition of a growing organisation with global capabilities and continuing commitment to advancing treatments for patients with psychiatric and neurological disorders
“I am deeply honored to join Clinilabs as Chief Executive Officer,” said Laura Shannon. “Gary and his team have built a truly differentiated, science-driven CRO with deep expertise in CNS drug and device development with a genuine commitment to developing therapies for patients. I am energized to lead this talented team with Gary and the rest of management to advance Clinilabs in its mission to bring better, safer, and more effective treatments to patients who need them most.”
"We are filled with immense pride and gratitude as we welcome Laura as our Chief Executive Officer and I transition to Executive Chairperson,” said Gary Zammit, Ph.D. “It has been the privilege of a lifetime to lead this remarkable organisation and to work alongside a team so deeply committed to improving the lives of patients with neurological disorders. Laura’s many years of biopharma leadership, track record of building high-performing teams, and deep expertise in commercial strategy and alliance management make her exceptionally well-suited to lead Clinilabs into its next chapter of growth.”
